Jon Adleberg, MD
Retina Specialist · Chesapeake, VANPI 1710981246
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,006 of the $20,501 with a category attached, or 68.3%. Cardinal Health 108 LLC accounts for 73.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $9,493 and has fallen 93.7% since, to $596 in 2025.
Across 183 payments — averaging $112.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardinal Health 108 LLC$15K
- Alimera Sciences, Inc.$813
- Genentech USA, Inc.$704
- Mallinckrodt Hospital Products Inc.$664
- Apellis Pharmaceuticals, Inc.$657
- AbbVie$438
- plus $2K from 13 others
Across 1 payment — averaging $750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$750
What the payments were for
- Consulting fees$14,00668%
- Travel & lodging$1,0475%
- Food & beverage$5,35526%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardinal Health 108 LLC | 7 | $15,089 |
| Alimera Sciences, Inc. | 32 | $813 |
| Genentech USA, Inc. | 22 | $704 |
| Mallinckrodt Hospital Products Inc. | 19 | $664 |
| Apellis Pharmaceuticals, Inc. | 14 | $657 |
| AbbVie(2 entities) | 26 | $438 |
| Regeneron Healthcare Solutions, Inc. | 13 | $427 |
| Novartis | 6 | $345 |
| Biogen | 7 | $342 |
| Coherus Oncology, Inc. | 9 | $235 |
| Astellas Pharma US Inc | 8 | $207 |
| Sandoz | 5 | $151 |
| Bausch & Lomb Americas Inc. | 4 | $148 |
| Eyepoint US, Inc. | 4 | $90 |
| Alcon | 1 | $57 |
| ANI Pharmaceuticals, Inc. | 2 | $41 |
| GSK | 2 | $39 |
| Harrow Eye, LLC | 1 | $29 |
| Vyera Pharmaceuticals, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,501 in reported general payments places this provider in the 85th percentile of 41 retina specialist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Timolol Maleate | 22 | $811 |
| Atropine Sulfate | 26 | $793 |
| Prednisolone Acetate | 26 | $658 |
| Ofloxacin | 21 | $348 |
| Latanoprost | 18 | $71 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Chesapeake
- Jordana FeinManassas$412K
- Joaquin TosiVirginia Beach$48K
- Mohit NandaCharlottesville$31K
- Muge KesenMc Lean$30K
- Anna MackinRoanoke$26K
- Dal ChunVienna$12K
- Kori ElkinsPortsmouth$9K
- Jiwei ShengFairfax$8K
- Timothy ByrnesRoanoke$7K
- Alexander MelamudFairfax$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.